On Saturday, AstraZeneca, a perceived frontrunner in the vaccine race, also announced it was resuming its COVID-19 vaccine trial in the UK after abruptly halting it earlier last week after 'a serious adverse reaction' occurred in one patient in its Phase 3 study in the UK which had only begun in late August.
An unnamed individual familiar with AstraZeneca's trial told the New York Times that the patient whose serious adverse reaction briefly halted the trial had symptoms "...consistent with inflammation of the spinal cord, known as transverse myelitis. The condition can be treated and is typically resolved in a few months, but severe attacks can cause major disabilities."
"100% transparency on COVID-19 vaccine trials is essential to public trust," said AHF president Michael Weinstein. "Despite corporate culture and potential market and/or political pressures falling on their heads, a leaders of these drug companies must be transparent about their vaccine trials. The damage done to the public trust from lack of transparency could be so great and so long-lasting that it could severely affect uptake of an eventual successful COVID vaccine as well as any other vaccines that follow."
AHF also repeated its call on the global public health community and governments to exercise caution and due diligence in fast-tracking vaccine candidates for prevention of COVID-19.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins